Refractory Ovarian Carcinoma Active Not Recruiting Phase 1 Trials for Aldesleukin (DB00041)

IndicationStatusPhase
DBCOND0110942 (Refractory Ovarian Carcinoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03691376Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTreatment